

## SPECIALTY GUIDELINE MANAGEMENT

### OXBRYTA (voxelotor)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Oxbryta is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older.

All other indications are considered experimental/investigational and not medically necessary.

##### II. CRITERIA FOR INITIAL APPROVAL

##### **Sickle cell disease (SCD)**

Authorization of 6 months may be granted for treatment of sickle cell disease in members 4 years of age or older with a pretreatment hemoglobin level of 10.5 g/dL or less.

Note: Requirements regarding pretreatment hemoglobin level exclude values due to a recent transfusion.

##### III. CONTINUATION OF THERAPY

##### **Sickle cell disease (SCD)**

Authorization of 12 months may be granted for continued treatment in members experiencing benefit from therapy demonstrated by increased hemoglobin levels or maintenance of increased hemoglobin levels since starting treatment.

##### IV. REFERENCES

1. Oxbryta [package insert]. South San Francisco, CA: Global Blood Therapeutics, Inc.; December 2021.
2. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. *N Engl J Med.* 2019 Aug 8;381(6):509-519.